Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
... to evaluate KRX-0401 (perifosine) as a single agent
treatment for recurrent solid tumors in pediatric ...
KRX-0401 is a novel, oral, anticancer agent
that modulates Akt and several other important ... Cancer Institute demonstrated that single agent
perifosine not only induced tumor regression and ...
CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
... obtained the rights to develop and market a novel agent
for the prevention and treatment of neuropathies ... CXB909, is a small molecule, orally active agent
that enhances the effects of nerve growth factor ... "In preclinical studies, our small molecule agent
CXB909 has been shown to increase the action of ...
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
Regardless of the particular anti-TNF-alpha agent
previously used in treatment (adalimumab, ... the efficacy and safety of an anti-TNF-alpha agent
in patients previously treated with other ... Reasons for discontinuation of prior anti-TNF agent
included lack of efficacy (58 percent), ...
Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
... KRX-0401 Demonstrates Impressive Single agent
Efficacy in Patients who Progressed after Failing ... as a secondary endpoint. Best response to single agent
perifosine was as follows:
Group ... group, best response and median PFS to single agent
perifosine was as follows:
TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
... to commonly used antimetabolite and alkylating agent
chemotherapies. The molecule is currently being studied as an oral agent
in combination with pemetrexed (Alimta(R)) and as an intravenous agent
in combination with temozolomide (Temodar(R)).
ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
... less toxic and more active than the FDA approved agent
ribavirin. Preliminary in vivo toxicology ...
"We believe that the addition of a novel agent
such as PG301029 to the current standard of care ... based on their transcription targeted therapeutic agent
For further information ...
Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
... our belief that ProLindac is an active platinum agent
with a favorable side effect profile," stated ... kill cancer cells; Alchemix, a chemotherapeutic agent
that combines multiple modes of action to ... ("PB"), an HDAC inhibitor and differentiating agent
currently a Phase 2 clinical candidate. Access ...
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
... benefit for pixantrone when used as single agent
therapy in the
treatment of multiple relapsed ... prior therapy with doxorubicin, an agent
in a similar class with
cumulative ... (BBR 2778), a DNA intercalating antitumor agent
an aza-anthracenedione molecular ...
Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
... the company's anticancer vascular-disrupting agent
The primary objectives of this ... and the dose-limiting toxicities (DLTs) for the agent
when administered orally in capsule form every ... intravenously. The oral activity of the agent
should markedly improve its clinical and ...
Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
... the program. The Altropane molecular imaging agent
is being developed by Alseres to aid in the early ... "We believe that Altropane represents an imaging agent
that is not only 'first-in-class' in the U.S. ... Altropane
Altropane is a molecular imaging agent
that specifically binds to the dopamine ...
Access Pharmaceuticals Presents new Combination Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
... mechanism. Angiolix(R) is a promising novel agent
for anti-angiogenic cancer therapy. Angiolix has ... kill cancer cells; Alchemix, a chemotherapeutic agent
that combines multiple modes of action to ... ("PB"), an HDAC inhibitor and differentiating agent
currently a Phase 2 clinical candidate. For ...
Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
... and efficacy of Macroplastique to another bulking agent
used in the control group. In the Macroplastique ... available bioabsorbable urethral bulking agent
for one year.
Of the 247 study ... Macroplastique(R) Implants, an injectable bulking agent
for the treatment of adult female stress urinary ...
FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
... Injection, an intravenous
for monitored anesthesia care (MAC) sedation in ... for
use as an intravenous sedative-hypnotic agent
for sedation in adult patients
undergoing ... LUSEDRA
is an intravenous sedative-hypnotic agent
indicated for monitored anesthesia
care (MAC) ...
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
... demonstrated that perifosine is an active, novel agent
with the potential to provide clinical benefit to ... Macroglobulinemia (WM)
perifosine achieved a 36% ORR (MR, PR) and 58% ... potentially first-in-class, oral anti-cancer agent
that modulates Akt and a number of other key ...
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Phase 2 Study of Voreloxin as Single agent
Therapy (REVEAL-1 Trial)
Interim data from ... E valuation of V or E loxin in A m L ) single agent
Phase 2 trial show that voreloxin induces ... Phase 2 portion of this study.
cytarabine is the current treatment standard for ...
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
... Receptor Antagonist (TRA), a novel antiplatelet agent
that can potentially prevent the formation of ... (golimumab), a once-monthly subcutaneous anti-TNF agent
for inflammatory and autoimmune disorders (under ... (asenapine), a novel psychopharmacologic agent
(under U.S. review for schizophrenia and acute ...
Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
... 1 dose escalation trial of
voreloxin as a single agent
in acute leukemias (N=73) showed that ... The researchers concluded that single agent
activity in the
relapsed/refractory AML ... voreloxin at a dose of
48 mg/m2 as a single agent
once every three weeks. At this dose, ...
PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
... on the battlefield or civilian victims of nerve agent
Valortim(R), in co-development with ... may
have efficacy as a therapeutic against nerve agent
-- A study of Valortim(R) in a ... mimics percutaneous exposure. In this model, free agent
measured in both the dermis and blood ...
Major State Grant Accelerates Research and Development of Novel Cancer Therapy
... developing an
over-the-counter skin protective agent
with unique antioxidant properties.
"SURECAG is ... compound that in
combination with an oxidizing agent
that generates reactive oxygen
Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
... of hematological malignancies as both a
and in combination with other therapies. This ... with leukemia. Laromustine is a promising agent
for that effort."
The trial has been designed ... evaluated in a Phase II pivotal trial as a
in elderly patients with previously untreated de ...
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
... causing apoptosis in cancer cells.
In single agent
Phase 1 studies carfilzomib has demonstrated ... currently evaluating carfilzomib as a single agent
for the treatment of
multiple myeloma in two ... is evaluating carfilzomib as a single agent
in a Phase 2 trial of
patients with advanced ...
Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
... RCC are warranted either as a single agent
or in combination with one
of the newer targeted ... antibody, bevacizumab (Avastin). Although
can provide some benefit in a subset of patients, ... in multiple tumor types both as a single agent
combination with other drugs. Agennix ...
Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Biotechnology intends to test the BPU agent
utilizing its Biomerk
Tumorgraft(TM) Preclinical ... preclinical models. By testing the
against panels of Biomerk Tumorgrafts from ... M.D., Ph.D.
Champions Biotechnology's BPU agent
is an antimitotic inhibitor that
targets MAPT ...
Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
... Will Bring Innovative Fluorescent Imaging agent
and System Technologies into Clinical ... treatment."
The ProSense(R) Activatable Imaging agent
platform was developed to
provide in vivo ... on the metabolism of the agent
to support expanded Phase II
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
... Data from Phase 1 Single agent
and Phase 1b Combination Clinical Trials ... Phase 1 trial of voreloxin when
used as a single agent
in relapsed or refractory patients with ... with
relapsed/refractory AML, and as a single agent
in a Phase 2 clinical trial
in platinum-resistant ...
Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma
... gadolinium has been shown to have single agent
lymphoma and is synergistic with ... Pharmacyclics is developing MGd as an anti-cancer agent
with a novel
mechanism of action that is designed ... non-overlapping toxicity makes it an appealing agent
to use in
combination with standard chemotherapy ...
Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
... phase 2
results demonstrating the single agent
clinical activity of perifosine in patients ... MA, discussed the phase 2
results on the single agent
clinical activity of perifosine in patients
with ... summary,
the investigators conclude that single agent
perifosine showed encouraging
activity with ...
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
... of Clolar(R)
(clofarabine) as a single agent
in previously untreated, older adult
patients ... prognostic factors who received single agent
exhibited a 45 percent overall ... efficacy findings we
are observing with single agent
clofarabine, we also see impressive
responses in ...
Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
preclinical activity of KRX-0401 as a single agent
and in combination with
novel agents are ... potentially first-in-class, oral
that modulates Akt and a number of other key ... variety of tumor types. KRX-0401 has
shown single agent
partial responses in renal cell and ...
Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
... development of this compound both as a single agent
and in combination
with other anti-cancer ... Phase 1b/2 clinical trials of XL765 as a single agent
combination with other targeted agents or ... efficacy in
xenograft models, both as a single agent
and in combination with other
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
... I/II clinical trial of its lead anticancer agent
(VNP40101M) in combination with ... of
these devastating conditions as both a single agent
and in combination with
Dr. ... evaluated in a Phase II pivotal trial as a single agent
patients with previously untreated de ...
Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
... is a new generation platinum
with the potential to become a platform ... this product."
Picoplatin is a chemotherapeutic agent
that has an improved safety
profile compared to ... position picoplatin as the
preferred platinum agent
for the first-line treatment of ...
Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
enrollment. ALTROPANE molecular imaging agent
is an investigational,
diagnostic drug developed ... nervous system diagnostic molecular imaging agent
-- and a valuable
tool to help clinicians make ... and their families.
About ALTROPANE Imaging agent
and Parkinsonian Syndromes Including
EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
... substantial, dose-dependent efficacy as a single agent
multiple preclinical models, including tumor ... models. Importantly, ENMD-2076 is an oral agent
that has shown
an acceptable toxicity profile in ... its
significant antitumor potential as a single agent
in a variety of tumor
types. Through this Phase 1 ...
Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure
"Debio 0614 is a novel intravenous agent
combining inotropic and
lusitropic properties. ... a trend to decrease heart rate, that makes this agent
promising therapy for the acute heart failure ... Debio 0614 is a first in class luso-inotropic agent
cycling modulating properties.
FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
... BFPET is
FluoroPharma's second cardiovascular PET agent
to enter clinical trials.
BFPET is a PET blood ... of 70:1, and we look forward to
evaluating the agent
in human studies."
"We are delighted to have ... progress
follows on the tail of CardioPET, an agent
for the detection of metabolic
integrity of the ...
OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
... -Provides Additional Evidence That This Phase II agent
Tolerability and Broad Anti-Microbial ... efficacy could make it a potentially valuable new agent
addressing a variety of ocular infections."
... drug, the pioneering gene silencing agent
entered a pivotal Phase III ...
Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
... with the related drug,
mitoxantrone, an agent
currently approved to treat severe ... [is] a promising immunosuppressant agent
suitable for clinical
investigation in myasthenia ... Pixantrone
Pixantrone is an investigational agent
under development for the
potential treatment of ...
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
... has recently shown very significant single agent
in a the difficult to treat elderly AML ... (VNP40101M) is an active agent
in AML, and we continue to
believe that it will ... and second
line settings, as either a single agent
or in combination with other
AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
... dacarbazine, and the immunotherapy agent
as a single agent
has minimal activity and interleukin 2 is not ... 10 years. In studies of
dacarbazine as a single agent
to treat malignant melanoma, median ...